Dialysis Patients' vaccine shield under microscope
NCT ID NCT06635525
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether kidney failure changes how well the flu vaccine works in people on dialysis. Researchers will compare the immune response of 146 dialysis patients and healthy volunteers after they get the flu shot. Participants will give blood samples over several months to track antibody levels.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 146 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2024
- Expected to finish
-
Jul 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study populations consist of (1) subjects with advanced chronic kidney disease requiring thrice-weekly hemodialysis, (2) subjects with advanced chronic kidney disease on peritoneal dialysis, and (3) subjects without a prior medical history of chronic kidney disease, who are eligible to receive an influenza vaccine according to standard clinical practice guidelines.
- Ages
-
18 to 70 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age between 18 and 70 years * Patients undergoing thrice-weekly hemodialysis / peritoneal dialysis for at least 3 months OR healthy individuals without a history of renal insufficiency * Subjects eligible to receive a seasonal influenza vaccine * Signed informed consent for participation in the study Exclusion Criteria: * Recent influenza infection (clinically resolved less than 3 months ago). * Administration of immunosuppressive drugs in the two weeks prior to vaccination. * Administration of another vaccine in the three weeks prior to enrollment (co-administration of other vaccines with those under study does not contraindicate participation). * Systemic infection clinically resolved less than two weeks before enrollment.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic kidney disease requiring chronic dialysis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
3 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
ASST Fatebenefratelli Sacco
NOT_YET_RECRUITINGMilan, 20157, Italy
-
ASST Santi Paolo e Carlo
NOT_YET_RECRUITINGMilan, 20142, Italy
-
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
RECRUITINGMilan, 20122, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug match a standard anemia treatment for dialysis patients?
- Scientists probe immune system secrets behind vaccines that protect for decades
- Could pumpkin seed oil ease inflammation in dialysis patients?
- Could a peptide supercharge COVID-19 vaccines for seniors?
- Why do flu shots weaken with age? new study aims to find out
- New pill could help dialysis patients control dangerous phosphate levels